John Challier Selected Research

RMFPNAPYL

12/2021

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John Challier Research Topics

Disease

5	Neoplasms (Cancer) 01/2022 - 12/2019
1	Hypoxia (Hypoxemia) 01/2022
1	Fever (Fevers) 01/2022
1	Hypotension (Low Blood Pressure) 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Leukemia 12/2021
1	Wilms Tumor (Wilm's Tumor) 12/2021
1	Carcinogenesis 01/2020
1	Hematologic Neoplasms (Hematological Malignancy) 12/2019

Drug/Important Bio-Agent (IBA)

4	Bispecific AntibodiesIBA 01/2022 - 12/2019
3	CytokinesIBA 01/2022 - 01/2021
3	Neoplasm Antigens (Tumor Antigens)IBA 12/2021 - 12/2019
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2021 - 01/2020
2	Peptides (Polypeptides)IBA 12/2021 - 01/2020
2	AntigensIBA 12/2021 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 12/2019
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	src-Family KinasesIBA 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2022
1	Janus Kinase InhibitorsIBA 01/2022
1	HLA-A Antigens (HLA-A)IBA 12/2021
1	WT1 ProteinsIBA 12/2021
1	RMFPNAPYLIBA 12/2021
1	Dasatinib (BMS 354825)FDA Link 01/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	AntibodiesIBA 01/2020
1	EpitopesIBA 01/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	Granzymes (Granzyme)IBA 12/2019
1	cibisatamabIBA 12/2019

Therapy/Procedure

2	Therapeutics 01/2022 - 12/2019
2	Immunotherapy 01/2022 - 12/2019